Monday, 21 December 2015

Compensation for Clinical Trial-related injury

methodology recommended for computing the compensation. We illustrate this by computing the sums to be paid under various assumptions, and then discuss the ethical dilemmas involved.

Formulae for computing compensation

The guidance recommends the following formula for computing compensation for a trial-related death (C1):
C1=A x B(1-F/100)
In this formula, 'A' is 50% of the participant's monthly income; this represents what the participant would be contributing to his/her dependents. If the monthly income is less than what it would be with the legal minimum wage, or if the participant does not have any monthly income, 'A' will consist of the legal minimum wage (calculated monthly).
'B' is a multiplier that is given and varies with the age of the research participant. In this case, age is taken as the age of the research participant at death or disability.
'F' is the seriousness or severity of the participant's disease at the time of recruitment into the trial. The compensation for a participant with a disease is computed as a fraction of what would be due to a healthy individual; for a healthy individual it would be 'A' x 'B' alone.
'F' is to be determined on a scale of 0 to 100, where '0' represents "no deviation from good health" and '100' represents death. The study investigator is required to set the seriousness or severity to this scale, while ensuring that the most serious or severe condition is not set at more than 50%. This means that even for participants for whom death is imminent due to an underlying health condition, the seriousness will not exceed 50%.
To determine compensation for injuries (C2), the guidance suggests the application of a different formula:
C2=A x B(1-F/100) x D/100
Here, 'A' is 60% of the participant's salary, representing the contribution for his/her dependents. 'B' varies with age, as it does in the formula for computing compensation for a participant's death. 'F' is the seriousness or severity of the disease at the time of participation. As the formula estimates the compensation for injuries and not death, another variable, 'D', is included: the percentage of disability caused to the participant due to trial participation. It is not clear how this is to be determined, but perhaps this is left to the ethics committee.

An alternative suggestion for estimating compensation

An attempt to mathematically compute the quantum of compensation has the potential to reduce a morally compelling act to one of administrative largesse, with attendant clerical rather than moral responsibility. It would be more advantageous and ethical to provide guidance to IECs on how to make this determination along the lines of what other countries have done (12) and leave the responsibility for determining the exact amount of compensation to them. The guidance could list the various criteria that need to be used and the rationale for these criteria, and the potential for trade-offs across criteria. Some possible criteria would be the extent of handicap in everyday social and professional life experienced by the participant as a result of the disability, the number of dependents and their characteristics, and so on. This would provide the flexibility required to manage the known criteria, and any others that may be recognised by the EC while undertaking this exercise. If such general guidance has served well in the determination of potential risks and benefits (which to this day have not been converted to an exact measurement of a net risk-benefit ratio), it would serve to determine a just compensation for a life lost or disabled. It has the potential to make ECs more meticulous in their engagement with research protocols. In the long run, one hopes that it would serve us to make death or disability due to clinical trial very rare for a participant.www.icbiocro.com

Sunday, 22 November 2015

Clinical Trial Supplies Market by Products & Services


Clinical Trial Supplies Market by Products & Services (Logistics & Distribution, Manufacturing, Packaging and Labeling), Phases (Phase I, Phase II, Phase III) & Therapeutic Areas (CNS & Mental Disorders, Cardiovascular, Oncology) - Global Forecast to 2020



The global clinical trial supplies market is expected to reach USD 1,274.3 Million by 2020 from USD 904.3 Million in 2015, at a CAGR of 7.1%. The global clinical trial supplies market is broadly classified into manufacturing services, packaging and labeling services, and logistics and distribution services. The logistics and distribution segment is expected to account for the largest share of the global clinical trial supplies products market in 2015.

read more about Clinical Trial Supplies

Wellness Supplements Market by Product (Dietary Supplements (Vitamin, Mineral, Protein, Herbal), - Global Forecast to 2020


The global Wellness Supplements market is expected to reach USD 249.4 Billion by 2020 from USD 183.1 Billion in 2015, at a CAGR of 6.4% during the forecast period. The growth of wellness supplement is mainly driven by factors such as rising geriatric population, growing prevalence of chronic diseases, rising awareness about benefits of wellness supplements, rising healthcare costs, and shift of consumers from care to preventive. However, regulatory compliance is likely to restrain the growth of wellness supplement market to a certain extent.

Clinical Trial Management System (CTMS) Market - Site Management, Billing & Patient recruitment, Cloud (SaaS) Global Trends, Opportunities, Challenges and Forecasts till 2016

A clinical trial deals with the application of specific clinical or scientific methods or medicine to the human body. Clinical trials are used to identify the effect of particular treatment or medication on patients suffering from a particular disease. The process of a clinical trial management system starts with identification of the medication or medical device to be tested. Participants for the trial are selected and the results are studied in order to define the effectiveness of the drug or device.

Clinical trials are very crucial as they involve huge capital investment and may affect the subjects involved. Thus proper management of clinical trials has become a priority for the hospitals. Clinical Trial Management System is a software system employed to manage the large amounts of data involved in a clinical trial. It maintains the planning, preparation, performance, and reporting of clinical trials, including participant information, trial and filing deadlines and other important milestones. The global market was valued at $576.22 million in 2010 and estimated to grow at a CAGR of 14.53% during the study period (2011-2016).

Improved clinical trial efficiency with optimized process; centralized database; improved site performance by enhanced investigator relationships; higher subject accrual rate & reduced workload for research coordinators; efficiency in budgeting and financial management; improved cost efficiencies; improved clinical research associate productivity; and automated data processing and report generating are some of the key advantages that are driving the market.

Clinical Trial Management System is used by the clinical trial organizations such as Pharmaceutical/Biopharmaceutical Companies, Clinical Research Organizations (CROs), and Healthcare providers (Hospitals, Academic Medical Centers (AMCs) which handle clinical trial. The pharmaceutical CTMS market contributed the largest share; i.e. 49% in 2010. Clinical Research Organizations (CRO) and Healthcare providers contributes 46% and 5% respectively in 2010.
Based on the mode of delivery, the global market is divided into three types; i.e. web-based, on-Premise and cloud-based. Among all these segments, the web-based market is forecasted to witness the highest CAGR of 15.95% from 2011 to 2016 and is estimated to capture 75% share by 2016 from 70% share in 2010. On-premise and cloud-based (SAAS) CTMS contributes 28% and 2% respectively in 2010.

North America dominated the global market with around 62% share in 2010. The U.S. captures the largest market share of North America, and shows a remarkable growth opportunity. The second largest market, Europe, while growth in the Asia-Pacific region is also expected to take greater curves in the near future.
Scope of the Report
This Clinical Trial Management Systems market research report will enable strategic understanding of the following key segments of the market:
Global market, by end-users:

26 new drugs permitted for sale without trials in India

New Delhi: Notwithstanding strong warnings by the parliamentary standing committee on health, new drugs continue to be approved for marketing in the country without holding any clinical trials on Indian patients to test their safety and efficacy
Sources in the Health Ministry admit that as many as 26 new drug molecules have been approved since 2010 without testing them through drug trials on local populations.
While eight new drug molecules of biologicals and non biologicals were approved by the country`s apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), last year, two have already been allowed for sale so far this year.www.icbiocro.com

Govt mulling 'structured regulatory regime' for AYUSH drugs

Government has considered setting up of a structured central regulatory regime for AYUSH drugs," AYUSH Minister Shripad Naik said in a written reply in Parliament.
He said that the current proposal is to have a vertical structure for AYUSH in the Central Drugs Standard Control Organisation (CDSCO).
"Procedural steps for setting up of this structure have been initiated, but the timeframe cannot be specified at this stage," he said.
The minister added that, presently, the Drugs and Cosmetics Act, 1940, and rules thereunder have exclusive provisions for AYUSH drugs, which are enforced by the state governments.
For regulating the practice of Ayurveda, Siddha, Unani and Homoeopathy (AYUSH) medicine, the government has established the Central Council of Indian Medicine and Central Council of Homoeopathy under the provisions of Indian Medicine Central Council Act, 1970, and the Homoeopathy Central Council Act, 1973, respectively, Naik said.
In another reply, the minister said that there are a total of 543 colleges of AYUSH currently functional in the country of which 281 are of Ayurveda, 191 of Homoeopathy, 44 of Unani, 18 of Naturopathy and nine of Siddha medicine.
"There are six states -- Manipur, Meghalaya, Mizoram, Nagaland, Sikkim and Tripura and four Union Territories -- Andaman and Nicobar Islands, Dadra and Nagar Haveli, Daman and Diu and Lakshadweep, where no AYUSH college has been established so far," he said.
The central government grants permission for the setting up of new Ayurveda, Siddha, Unani (ASU) and Homoeopathy Medical Colleges under the provisions of Section 13A of the Indian Medicine Central Council Act, 1970, and Section 12A of the Homoeopathy Central Council Act, 1973, respectively.
"There is no Central Act and Regulatory Central Council for Yoga and Naturopathy," he said.
Naik added that a total of 92 proposals have been received during 2015 from various institutions (private as well as government) in the various states/UTs for the opening of new Ayurveda, Siddha, Unani and Homoeopathy medical colleges of which 63 proposals are for Ayurveda colleges and 22 for Homoeopathy.